50 related articles for article (PubMed ID: 22214004)
1. [Efficacy of monoclonal antibodies in combination with chemotherapy in metastatic colorectal cancer].
Takiuchi H
Nihon Rinsho; 2011 Apr; 69 Suppl 3():459-63. PubMed ID: 22214004
[No Abstract] [Full Text] [Related]
2. [Issues of molecular targeted therapies in combination with chemotherapy in metastatic colorectal cancer].
Asayama M; Kadowaki S; Yamaguchi K
Nihon Rinsho; 2011 Apr; 69 Suppl 3():464-71. PubMed ID: 22214005
[No Abstract] [Full Text] [Related]
3. [Molecular target therapy for colorectal cancer].
Uetake H; Ishikawa T; Sugihara K
Nihon Geka Gakkai Zasshi; 2011 Jan; 112(1):39-42. PubMed ID: 21387600
[No Abstract] [Full Text] [Related]
4. Chemotherapy of metastatic colorectal cancer.
Prescrire Int; 2010 Oct; 19(109):219-24. PubMed ID: 21180382
[TBL] [Abstract][Full Text] [Related]
5. Optimal treatment of metastatic colorectal cancer.
Pessino A; Sobrero A
Expert Rev Anticancer Ther; 2006 May; 6(5):801-12. PubMed ID: 16759170
[TBL] [Abstract][Full Text] [Related]
6. Treatment of metastatic colorectal cancer.
Davies JM; Goldberg RM
Semin Oncol; 2011 Aug; 38(4):552-60. PubMed ID: 21810514
[TBL] [Abstract][Full Text] [Related]
7. [Chemotherapy for metastatic colorectal cancer].
Iwasa S; Shimada Y
Gan To Kagaku Ryoho; 2008 Sep; 35(9):1467-74. PubMed ID: 18799899
[TBL] [Abstract][Full Text] [Related]
8. Systemic therapy for advanced or metastatic colorectal cancer: National Comprehensive Cancer Network guidelines for combining anti-vascular endothelial growth factor and anti-epidermal growth factor receptor monoclonal antibodies with chemotherapy.
Engstrom PF;
Pharmacotherapy; 2008 Nov; 28(11 Pt 2):18S-22S. PubMed ID: 18980548
[TBL] [Abstract][Full Text] [Related]
9. Cetuximab: new drug. Metastatic colorectal cancer: an inappropriate evaluation.
Prescrire Int; 2005 Dec; 14(80):215-7. PubMed ID: 16400742
[TBL] [Abstract][Full Text] [Related]
10. [Towards an individualized treatment of the colorectal cancer: a new therapy against EGFR opens the way].
Sylviane O
Med Sci (Paris); 2009 Mar; 25 Spec No 1():7-8. PubMed ID: 19361403
[No Abstract] [Full Text] [Related]
11. [Team medicine in chemotherapy for metastatic colorectal cancer].
Muro K
Gan To Kagaku Ryoho; 2013 Apr; 40(4):435-9. PubMed ID: 23848010
[TBL] [Abstract][Full Text] [Related]
12. [Trends in development of molecular targeted therapy for hematological neoplasms].
Nagai T
Rinsho Ketsueki; 2012 Oct; 53(10):1768-75. PubMed ID: 23037750
[No Abstract] [Full Text] [Related]
13. Colorectal cancer drugs market.
Cassidy S; Syed BA
Nat Rev Drug Discov; 2017 Aug; 16(8):525-526. PubMed ID: 28529321
[No Abstract] [Full Text] [Related]
14. Monoclonal antibodies may help locate and treat occult metastases.
Oncology (Williston Park); 1996 Apr; 10(4):552. PubMed ID: 8723285
[No Abstract] [Full Text] [Related]
15. Edrecolomab in the adjuvant treatment of colorectal carcinoma.
Alliot C
Lancet; 2003 Jan; 361(9351):82; author reply 83. PubMed ID: 12517501
[No Abstract] [Full Text] [Related]
16. Edrecolomab in the adjuvant treatment of colorectal carcinoma.
Spizzo G; Obrist P; Went P; Dirnhofer S; Gastl G
Lancet; 2003 Jan; 361(9351):83; author reply 83. PubMed ID: 12517502
[No Abstract] [Full Text] [Related]
17. [Selection of a molecule-target agent--present and prospect].
Takahashi N; Hamaguchi T
Nihon Rinsho; 2011 Apr; 69 Suppl 3():482-6. PubMed ID: 22214008
[No Abstract] [Full Text] [Related]
18. The challenge to optimize medical therapy for advanced colorectal cancer.
Hubbard JM; Grothey A
J Natl Cancer Inst; 2014 Feb; 106(2):djt442. PubMed ID: 24511110
[No Abstract] [Full Text] [Related]
19. Progress in the development of monoclonal antibody therapies for colorectal cancer. Introduction.
Goodin S
Am J Health Syst Pharm; 2008 Jun; 65(11 Suppl 4):S2. PubMed ID: 18499886
[No Abstract] [Full Text] [Related]
20. [Recent progress in research of colorectal cancer].
Inoue M
Nihon Shokakibyo Gakkai Zasshi; 2012 Dec; 109(12):2007-13. PubMed ID: 23221048
[No Abstract] [Full Text] [Related]
[Next] [New Search]
